Submission Reinforces Commitment to Immune Therapy in the US marketplace YONGIN, South Korea, Nov. 24, 2015 /PRNewswire/ — Green Cross Corporation (Green Cross), a South Korean biopharmaceutical company, today announced that it has submitted its Biologics License Application for IVIG-SN (human normal immunoglobulin G for intravenous administration) to the United States Food and Drug Administration (FDA).…